GLP1R and type 2 diabetes mellitus: In recent developments, tirzepatide, a dual gastric inhibitory peptide (GIP) and GLP-1 receptor agonist, has demonstrated favorable modulation of metabolites related to insulin resistance and future T2DM risk, with more significant reductions in HbA1c levels, HOMA-IR, and improvement in dyslipidemic profiles compared to dulaglutide and placebo, leading to an overall enhancement of metabolic health [151].